MSN Laboratories Private Limited

MSN Laboratories Private Limited, established on August 27, 2003, is a Hyderabad-based pharmaceutical company committed to providing affordable healthcare solutions. The company is registered under the Corporate Identification Number (CIN) U24239TG2003PTC041583. As of March 2026, MSN Laboratories has an authorized capital of ₹100 crore and a paid-up capital of ₹52 crore. The company employs over 15,000 professionals, reflecting its significant presence in the pharmaceutical industry. MSN Laboratories operates across multiple countries, including the USA, Indonesia, and the UAE, with a diverse product portfolio encompassing over 500 APIs and 400 formulations across 35 major therapeutic areas.

MSN Laboratories operates 17 Active Pharmaceutical Ingredient (API) facilities and 8 finished dosage form (FDF) facilities across India, the USA, Indonesia, and the UAE. These facilities are equipped with state-of-the-art technology to ensure the production of high-quality pharmaceutical products. The company's manufacturing plants specialize in a wide range of therapeutic categories, including cardiovascular, oncology, and Ayurvedic & herbal products, catering to diverse global healthcare needs.

The leadership team at MSN Laboratories includes:

• Satyanarayana Reddy Manne: Managing Director since August 27, 2003.

• Bharat Reddy Chintapally: Director since February 1, 2007.

• Laxmi Prasuna Manne: Director since August 27, 2003.

These leaders have been instrumental in steering the company towards its mission of delivering affordable healthcare solutions globally.

MSN Laboratories has established a strong presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained approvals for its finished pharmaceutical formulations from various regulatory bodies, ensuring compliance with international standards. This regulatory compliance facilitates access to these markets, enabling MSN Laboratories to supply a wide range of pharmaceutical products to meet global healthcare demands.

MSN Laboratories has expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's products have been prequalified by the World Health Organization (WHO), which is a significant achievement that enhances its credibility and facilitates market access in these regions. This prequalification enables MSN Laboratories to supply essential medicines to countries with stringent regulatory requirements, thereby contributing to global health initiatives.

MSN Laboratories' geographic strategy demonstrates a balanced approach to market diversification. While the company has a strong presence in regulated markets, it has also made significant inroads into emerging markets, reducing concentration risk. This strategic diversification allows MSN Laboratories to mitigate potential market fluctuations and leverage growth opportunities across different regions.

MSN Laboratories has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), ensuring compliance with U.S. regulatory standards. The company has filed multiple Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs), facilitating the approval of its generic pharmaceutical products in the U.S. market. FDA inspections have been conducted at various facilities, with the most recent Form 483 issued on June 25, 2024, indicating ongoing compliance efforts.

MSN Laboratories has achieved prequalification from the World Health Organization (WHO), a testament to the quality and safety of its pharmaceutical products. The company has also obtained Good Manufacturing Practice (GMP) certifications from the European Union (EU), ensuring adherence to stringent manufacturing standards required for market access in EU member countries. These certifications underscore MSN Laboratories' commitment to maintaining high-quality manufacturing processes.

In India, MSN Laboratories holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), authorizing the production of pharmaceutical formulations. The company has obtained approvals from various state drug controllers, facilitating the distribution of its products across different states. Additionally, MSN Laboratories has secured export No Objection Certificates (NOCs), enabling the export of its pharmaceutical products to international markets.

MSN Laboratories has undergone multiple FDA inspections, with the most recent Form 483 issued on June 25, 2024. These inspections are part of the FDA's routine process to ensure compliance with U.S. regulatory standards. The company has addressed the observations noted in these inspections, demonstrating its commitment to maintaining high-quality manufacturing practices.

In the cardiovascular therapeutic category, MSN Laboratories faces competition from other Indian pharmaceutical companies such as Aurobindo Pharma and Dr. Reddy's Laboratories. MSN Laboratories holds a 7.7% market share in atorvastatin and a 12.7% market share in rosuvastatin, indicating a strong position in this segment. In the antiviral segment, particularly for oseltamivir, MSN Laboratories competes with global pharmaceutical companies, holding a 10.0% market share. The company's diverse product portfolio across 15 therapeutic categories allows it to mitigate competitive pressures in any single market segment.

MSN Laboratories' key differentiators include its extensive product portfolio, encompassing over 500 APIs and 400 formulations across 35 major therapeutic areas. The company's integrated research and development center for both APIs and formulations enables rapid product development and market entry. Additionally, MSN Laboratories' commitment to affordability and accessibility has earned it the trust of over 50 million patients across more than 100 countries.

MSN Laboratories maintains a strategic focus on generics, with a significant emphasis on cardiovascular and antiviral products. The company's portfolio also includes Ayurvedic and herbal products, reflecting a commitment to diverse therapeutic areas. Looking ahead, MSN Laboratories aims to expand its presence in emerging markets and continue to innovate in the development of affordable healthcare solutions.

MSN Laboratories has demonstrated a strong track record in pharmaceutical manufacturing, with a total export value of $252.1 million USD and 8,837 shipments across 32 products in 15 therapeutic categories. The company's top five products—atorvastatin, rosuvastatin, ras, oseltamivir, and calcium—account for 73.4% of its portfolio, indicating a focused approach to product development. The company's consistent growth and adherence to international quality standards make it a reliable supplier in the pharmaceutical industry.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Registration: Confirm the company's manufacturing facilities are registered with the U.S. Food and Drug Administration.

• WHO Prequalification: Ensure the company's products are prequalified by the World Health Organization.

• EU GMP Certification: Verify the company holds Good Manufacturing Practice certification from the European Union.

• ISO Certification: Check for ISO certifications related to quality management systems.

These certifications can typically be verified through the respective regulatory bodies' official websites or by requesting documentation directly from the supplier.

When conducting due diligence on MSN Laboratories, consider the following steps:

• Verify Regulatory Approvals: Confirm that the company's products have the necessary approvals from relevant regulatory authorities in target markets.

• Review Manufacturing Practices: Assess the company's adherence to Good Manufacturing Practices (GMP) and other quality standards.

• Evaluate Financial Stability: Examine the company's financial statements to ensure stability and capacity for large-scale production.

• Assess Supply Chain Reliability: Evaluate the consistency and reliability of the company's supply chain to meet delivery commitments.

• Check for Compliance Issues: Investigate any past regulatory actions, such as warning letters or import alerts, to assess the company's compliance history.

Red flags to watch for include unresolved regulatory issues, financial instability, and inconsistent product quality. Recommended pre-order checks involve requesting recent inspection reports, financial audits, and product samples for quality assessment.